JAK2 V617F Mutation Detection in Mice: Comprehensive Molecular Biology Testing Services

JAK2 V617F mouse molecular biology detection provides researchers with precise genotyping and quantification of the JAK2 V617F somatic mutation in murine models of myeloproliferative neoplasms. Using allele-specific PCR, quantitative real-time PCR, and sequencing technologies, this service supports disease mechanism studies, drug efficacy evaluation, and translational research. Accurate mutation detection is essential for validating knock-in mouse models, monitoring tumor burden, and advancing hematological research.

Technical Overview

The JAK2 V617F mutation is a somatic gain-of-function point mutation located in exon 14 of the Janus kinase 2 (JAK2) gene, resulting in a valine-to-phenylalanine substitution at codon 617 within the pseudokinase (JH2) domain. This mutation disrupts the autoinhibitory function of the JH2 domain, leading to constitutive activation of the JAK-STAT signaling pathway. In humans, JAK2 V617F is the hallmark driver mutation of Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

Mouse models carrying the Jak2 V617F mutation, including conditional knock-in models such as Jak2^V617F/+ mice with loxP-flanked exon sequences, faithfully recapitulate the human MPN phenotype, presenting with erythrocytosis, leukocytosis, splenomegaly, and progressive myelofibrosis. Molecular detection of the mutant allele in these mice is critical for genotype confirmation, quantification of mutant allele burden, monitoring disease progression, and evaluating therapeutic responses in preclinical studies.

Testing Samples

Peripheral Blood

Peripheral blood collected from the tail vein, retro-orbital sinus, or submandibular vein is the most commonly used sample type for longitudinal monitoring. EDTA or heparin anticoagulants are recommended, and genomic DNA is extracted from leukocytes after red blood cell lysis. Serial blood sampling allows researchers to track mutant allele dynamics over time without sacrificing the animal.

Bone Marrow Cells

Bone marrow harvested from femurs, tibias, and iliac crests provides the highest concentration of hematopoietic cells carrying the mutation. Bone marrow aspirates or flushed cells are suitable for genotyping, mutant allele burden quantification, and clonal analysis of hematopoietic stem and progenitor cell populations.

Spleen and Other Organs

Splenomegaly is a characteristic feature of Jak2 V617F-driven disease, and extramedullary hematopoiesis in the spleen often contains a high proportion of mutant cells. Spleen tissue, along with liver, lymph nodes, and other affected organs, can be snap-frozen or fixed for DNA extraction and mutation analysis.

Genomic DNA Samples

Pre-extracted high-quality genomic DNA is accepted for direct testing. Samples should have an A260/A280 ratio between 1.8 and 2.0, sufficient concentration, and verified integrity to ensure reliable amplification results.

Testing Items

Our JAK2 V617F molecular biology testing portfolio encompasses the following items:

• Jak2 V617F genotype identification in knock-in or transgenic mouse colonies
• Quantitative detection of mutant allele burden (mutant allele frequency)
• Cre-mediated recombination efficiency assessment in conditional alleles (Jak2^VF/+ models)
• Tissue distribution profiling of the mutant allele across multiple organs
• Serial monitoring of mutant clone dynamics during disease progression
• Drug treatment response evaluation based on allele burden reduction
• Verification of zygosity and germline transmission in breeding programs
• Sanger sequencing confirmation of PCR amplicons spanning codon 617

Testing Methods

Allele-Specific PCR (AS-PCR)

Allele-specific PCR utilizes primers whose 3' terminus specifically matches either the wild-type or mutant nucleotide at the V617F locus. Amplification occurs only when the primer fully anneals to the complementary template, allowing discrimination between wild-type and mutant alleles. This method is highly sensitive, cost-effective, and suitable for routine genotyping of breeding colonies.

Allele-Specific Quantitative PCR (AS-qPCR)

Real-time quantitative PCR with allele-specific TaqMan probes or SYBR Green chemistry enables precise quantification of the mutant allele fraction. Wild-type and mutant reactions are run in parallel with standard curves generated from serially diluted plasmid controls of known allele ratios. This approach achieves a sensitivity of approximately 0.1–1% mutant allele and is the preferred method for monitoring allele burden dynamics in therapeutic studies.

Sanger Sequencing

PCR amplification of the genomic region flanking codon 617 in exon 14, followed by capillary Sanger sequencing, provides direct confirmation of the mutation. While its analytical sensitivity is limited to detecting mutant alleles above approximately 10–20% of total alleles, Sanger sequencing remains the gold standard for sequence verification and exclusion of unexpected variants in the amplicon region.

Droplet Digital PCR (ddPCR)

Droplet digital PCR partitions the reaction into thousands of individual droplets, enabling absolute quantification of mutant and wild-type alleles without standard curves. ddPCR offers superior sensitivity, detecting mutant allele frequencies as low as 0.01–0.1%, making it ideal for minimal residual disease assessment and low-level chimerism studies in transplantation experiments.

Next-Generation Sequencing (NGS)

Targeted amplicon-based deep sequencing provides comprehensive mutation profiling with high depth of coverage, allowing simultaneous detection of JAK2 V617F and co-occurring mutations in genes such as TET2, ASXL1, DNMT3A, and CALR. NGS is recommended for clonal evolution studies and comprehensive genomic characterization of disease models.

Applications

Molecular detection of Jak2 V617F in mice supports a wide range of research applications:

• Phenotypic validation and colony management of Jak2 V617F knock-in mouse strains
• Pathogenesis research on myeloproliferative neoplasms, including polycythemia vera and myelofibrosis
• Preclinical efficacy evaluation of JAK inhibitors and novel targeted therapies
• Hematopoietic stem cell transplantation and disease-initiating cell studies
• Inflammation and thrombosis research associated with JAK-STAT pathway activation
• Drug safety and pharmacodynamic biomarker studies
• Comparative studies of JAK2 V617F with other MPN-associated mutations such as CALR and MPL
• Investigation of clonal evolution and mutation order in myeloid malignancies

FAQ

What is the sensitivity of JAK2 V617F detection?

Detection sensitivity depends on the method employed. Allele-specific qPCR typically detects mutant allele frequencies down to 0.1–1%, while droplet digital PCR can achieve sensitivity of 0.01–0.1%. Sanger sequencing requires a mutant allele fraction of at least 10–20% for reliable detection.

How much sample is required for testing?

For peripheral blood, 20–50 microliters are generally sufficient for a single qPCR assay. Tissue samples of 10–20 milligrams yield adequate genomic DNA. We recommend providing at least 200 nanograms of purified genomic DNA when submitting pre-extracted samples to accommodate repeat testing if necessary.

How long does the testing take?

Standard turnaround time is 5–7 business days from sample receipt for routine genotyping. Quantitative allele burden analysis and sequencing confirmation may require 7–10 business days depending on sample volume and assay complexity.

Can the assay distinguish homozygous from heterozygous mutants?

Yes, quantitative allele-specific PCR accurately measures mutant allele fraction, distinguishing homozygous mutants (approximately 100%), heterozygotes (approximately 50%), and wild-type animals. This is particularly important because loss of heterozygosity and mitotic recombination can drive conversion to homozygosity during disease progression.

How should samples be stored and shipped?

Blood samples should be collected into EDTA tubes and shipped at 4°C within 48 hours. Tissues should be snap-frozen in liquid nitrogen and shipped on dry ice. Extracted genomic DNA can be shipped at ambient temperature or 4°C. Avoid repeated freeze-thaw cycles to preserve DNA integrity.